Endothelial inflammatory and vasoactive pathways

Endothelial inflammatory and vasoactive pathways encompass the integrated molecular systems within the vascular endothelium that maintain cardiovascular homeostasis by regulating blood flow and immune cell interactions (Gimbrone & García-Cardeña, 2016, Circulation Research). These pathways involve a delicate balance between vasodilators, such as nitric oxide and prostacyclin, and vasoconstrictors like endothelin-1 and thromboxane A2 (Vanhoutte et al., 2017, British Journal of Pharmacology). In response to stimuli like oxidative stress or high glucose, the endothelium becomes activated, leading to the upregulation of adhesion molecules (e.g., VCAM-1, ICAM-1) and pro-inflammatory cytokines that promote leukocyte recruitment and plaque formation (Libby et al., 2018, Journal of the American College of Cardiology). Dysregulation of these pathways is a primary driver of endothelial dysfunction, which underlies the pathogenesis of atherosclerosis, hypertension, and diabetic vasculopathy (NIH, 2023). Pharmacological intervention often focuses on restoring nitric oxide signaling or blocking the effects of potent vasoconstrictors and inflammatory mediators to prevent or treat vascular disease (StatPearls, 2023).

Other names

Endothelial dysfunction pathwaysVascular inflammatory signalingVasoactive signaling cascadesEndothelial activation pathways

Drugs targeting these pathways typically work by enhancing nitric oxide bioavailability, inhibiting the production or action of vasoconstrictors like endothelin-1 and angiotensin II, or reducing the expression of pro-inflammatory cytokines and adhesion molecules.